Intra Cellular Therapies Top Insiders
ITCIDelisted Stock | USD 131.87 0.03 0.02% |
Intra Cellular employs about 860 people. The company is managed by 16 executives with a total tenure of roughly 52 years, averaging almost 3.0 years of service per executive, having 53.75 employees per reported executive. Assessment of Intra Cellular's management performance can provide insight into the firm performance.
Sharon Mates Chairman Co-Founder, Chairman, CEO and Pres |
Robert Davis President Senior Vice President and Chief Scientific Officer |
Intra |
Intra Cellular's latest congressional trading
Congressional trading in companies like Intra Cellular Therapies, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Intra Cellular by those in governmental positions are based on the same information available to the general public.
2025-05-14 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
2025-05-07 | Representative Gilbert Cisneros | Acquired Under $15K | Verify | ||
2025-04-11 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
2025-04-08 | Representative Gilbert Cisneros | Acquired Under $15K | Verify |
Intra Cellular Management Team Effectiveness
The company has return on total asset (ROA) of (0.0696) % which means that it has lost $0.0696 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0858) %, meaning that it created substantial loss on money invested by shareholders. Intra Cellular's management efficiency ratios could be used to measure how well Intra Cellular manages its routine affairs as well as how well it operates its assets and liabilities.Intra Cellular Workforce Comparison
Intra Cellular Therapies is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 18,127. Intra Cellular holds roughly 860 in number of employees claiming about 5% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.11) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.15) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.15. Intra Cellular Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intra Cellular insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intra Cellular's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Intra Cellular insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mark Neumann over three months ago Disposition of 52811 shares by Mark Neumann of Intracellular at 132.0 subject to Rule 16b-3 | ||
Sharon Mates over three months ago Acquisition by Sharon Mates of 190000 shares of Intracellular subject to Rule 16b-3 | ||
Mark Neumann over three months ago Acquisition by Mark Neumann of 7345 shares of Intracellular subject to Rule 16b-3 | ||
Halstead Michael over three months ago Disposition of 7345 shares by Halstead Michael of Intracellular subject to Rule 16b-3 | ||
Halstead Michael over three months ago Disposition of 13133 shares by Halstead Michael of Intracellular subject to Rule 16b-3 | ||
Mark Neumann over three months ago Acquisition by Mark Neumann of 18714 shares of Intracellular at 36.89 subject to Rule 16b-3 | ||
Mark Neumann over three months ago Acquisition by Mark Neumann of 11017 shares of Intracellular subject to Rule 16b-3 | ||
Durgam Suresh K. over three months ago Disposition of 4730 shares by Durgam Suresh K. of Intracellular at 127.0 subject to Rule 16b-3 |
Intra Cellular Notable Stakeholders
An Intra Cellular stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Intra Cellular often face trade-offs trying to please all of them. Intra Cellular's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Intra Cellular's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Sharon Mates | Co-Founder, Chairman, CEO and Pres | Profile | |
Robert Davis | Senior Vice President and Chief Scientific Officer | Profile | |
Mark Neumann | Executive Vice President Chief Commercial Officer | Profile | |
Juan Sanchez | Vice President - Corporate Communications and Investor Relations | Profile | |
John Bardi | Senior Vice President - Market Access, Policy and Government Affairs | Profile | |
John Condon | General President | Profile | |
Michael Olchaskey | Senior Vice President Head of Regulatory Affairs | Profile | |
Sanjeev Narula | Executive CFO | Profile | |
Lawrence CPA | CFO, Finance | Profile | |
Michael JD | General VP | Profile | |
CPA CPA | CFO, Fin | Profile | |
Juan MD | Vice Relations | Profile | |
Michael PharmD | Senior Affairs | Profile | |
Suresh MD | Executive Officer | Profile | |
Karen Esq | Senior Officer | Profile | |
Willie MD | Senior Development | Profile |
About Intra Cellular Management Performance
The success or failure of an entity such as Intra Cellular Therapies often depends on how effective the management is. Intra Cellular management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Intra management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Intra management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.
Intra Cellular Workforce Analysis
Traditionally, organizations such as Intra Cellular use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Intra Cellular within its industry.Intra Cellular Manpower Efficiency
Return on Intra Cellular Manpower
Revenue Per Employee | 791.7K | |
Revenue Per Executive | 42.6M | |
Net Loss Per Employee | 86.8K | |
Net Loss Per Executive | 4.7M | |
Working Capital Per Employee | 1.3M | |
Working Capital Per Executive | 68.9M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Intra Stock
If you are still planning to invest in Intra Cellular Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intra Cellular's history and understand the potential risks before investing.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |